Iovance Biotherapeutics
IOVA | NASDAQ
$7.55
-$0.21 (-2.71%)
At close: Nov 16, 2026, 4:00 PM ET
$7.48
-$0.07 (-0.93%)
After-hours:
Nov 16, 2026, 7:59 PM ET
Iovance Biotherapeutics Company Profile
Company profile explainedCompany Profile
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Key Executives
| Name | Position |
|---|---|
| Frederick G. Vogt | Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director |
| Corleen Roche | Chief Financial Officer |
| Igor Bilinsky | Chief Operating Officer |
| Brian Gastman | Executive Vice President of Translational Medicine & Research |
| Daniel G. Kirby | Chief Commercial Officer |
| Howard Johnson | Chief Business Officer |
| Kevin Smyth | Executive Vice President of Quality |
| Raj K. Puri | Chief Regulatory Officer |
| Sara Pellegrino | Senior Vice President of Investor Relations & Corporate Communications |
| Tracy Winton | Executive Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 3 | Filing |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
Iovance Biotherapeutics
| Country | United States |
| IPO Date | Oct 15, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 975 |
| CEO | Frederick G. Vogt |
Contact Details
825 Industrial Road San Carlos,
California 94070 United States
Stock Details
| Ticker Symbol | IOVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001425205 |
| CUSIP Number | 462260100 |
| ISIN Number | US4622601007 |
| SIC Code | 2836 |
Recent News
- 16 hours ago / marketbeat.comIovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb
- 23 hours ago / seekingalpha.comIovance: The Lung Selloff Went Too Far For A Business Growing 77%
- 4 days ago / globenewswire.comIovance Biotherapeutics to Present at Upcoming Conference
- 11 days ago / zacks.comIOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs
- 11 days ago / seekingalpha.comIovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market Reaction
- 11 days ago / seekingalpha.comIovance: Reset Expectations Make The Stock A Buy Again (Rating Upgrade)
- 11 days ago / zacks.comIOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress
- 11 days ago / seekingalpha.comIovance Biotherapeutics, Inc. (IOVA) Q3 2026 Earnings Call Transcript
- 11 days ago / marketbeat.comIovance Biotherapeutics Q3 Earnings Call Highlights
- 12 days ago / zacks.comIovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue Estimates
Add to Watchlist
Select watchlists to add or remove IOVA